Eli Lilly is trading lower as investors react to weekly U.S. prescription tracking that showed mixed-to-slightly softer trends across the company’s GLP-1 franchise. For the week ending April 17, 2026, combined prescriptions for Mounjaro, Trulicity, Zepbound, and the newly launched oral option Foundayo fell about 0.3% week over week (to ~1.503 million). While Lilly’s overall weekly new-prescription share held around 59%, the small decline and the competitive context are pressuring sentiment. (investing.com)

The sharper focus is on early launch traction for Foundayo. In its second week on the market, Foundayo logged roughly 3,700 total/new prescriptions, compared with roughly 18,400 total/new prescriptions for oral Wegovy in its second week after a January 5, 2026 launch—an unfavorable early comparison that is raising questions about how quickly Lilly can scale an oral obesity option versus entrenched competitors. (investing.com)

Beyond weekly scripts, the market is also weighing the evolving reimbursement and access backdrop for obesity drugs. The federal government has indicated it is delaying the BALANCE Medicare pilot that was designed to broaden access, reinforcing investor sensitivity to near-term coverage uncertainty even as demand remains strong. As a result, near-term price action is increasingly being driven by competitive positioning and channel access signals rather than just headline demand growth. (axios.com)